Pharmaceutical Executive (@PharmExec) header
Pharmaceutical Executive (@PharmExec) profile picture

Official Twitter account for Pharmaceutical Executive, a digital and print magazine offering news and opinions, analysis, features and executive profiles.

London & New Jersey
Joined February 2009
Photo by Pharmaceutical Executive (@PharmExec)Photo by Pharmaceutical Executive (@PharmExec)Photo by Pharmaceutical Executive (@PharmExec)Photo by Pharmaceutical Executive (@PharmExec)Photo by Pharmaceutical Executive (@PharmExec)Photo by Pharmaceutical Executive (@PharmExec)Photo by Pharmaceutical Executive (@PharmExec)Photo by Pharmaceutical Executive (@PharmExec)Photo by Pharmaceutical Executive (@PharmExec)Photo by Pharmaceutical Executive (@PharmExec)
🚨Our March issue is LIVE🚨 Learn about immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics in our cover profile🔷 Sourcing, nurturing, and retaining talent🔷Making HCP analytics actually work for commercial teams🔷and much more right here➡️pharmexec.com/journals/pharm…
3
4
10
3,188
This month in pharma ⬇️ Pfizer & Blackstone’s $1.5B obesity drug funding deal, new FDA approvals for Cosentyx and Wilserdly, and Lilly’s $3.5B PA manufacturing plant. 🔍 Get the full breakdown: hubs.li/Q04FK8y70 #PharmExec #GLP1
2
148
Agent-first, but human when it matters most. That’s how Infinitus CEO Ankit Jain frames pharma’s AI workload shift, agents handling the first line of response, humans stepping in for exceptions & regulated calls. More here➡️: hubs.li/Q04FKjml0 #PharmaExecutive #AI
225
CGT success is often limited not by the science, but by execution. Cencora’s Louis Cicchini on the early, cross-functional decisions that keep launches on track. 🔗 Read where siloed planning creates barriers: hubs.li/Q04DjG3f0 #Pharma
152
A bone marrow transplant that used to take 12-15 weeks can now happen in as little as 31 hours. Kevin Caldwell of Ossium Health on banking marrow from deceased donors, on The Ron Lanton Report. Listen here➡️ hubs.li/Q04Fp9Z60 #Biopharma #CellTherapy
1
299
7,000+ state legislative seats and 36 governorships were on the ballot this cycle, and drug pricing policy is following the results. PhRMA’s Scott LaGanga tells Pharm Exec’s Mike Christel why PBM reform is a state fight now. 🎧 Listen: hubs.li/Q04Fhhkt0 #PharmExec
1
311
Maximizers & accumulators put the value of every affordability dollar at risk. @Paysign’s Matt Turner on turning claims data into a proactive defense. 📽️ Get the long-term vision for ClaimGuardRx: hubs.li/Q04CtJcL0 #Pharma
1
253
A tumor you treated six months ago may not be the tumor you’re treating today. Dr. Brian Corgiat senior clinical research scientist at Ignite Proteomics says testing needs to catch up to the tumor as it is now, not as it was at diagnosis. See the full interview ➡️ hubs.li/Q04DWynl0 #Oncology #PrecisionMedicine
178
Repurposed fraud tools weren’t built for patient affordability claims. ClaimGuardRx’s LLM was. @Paysign’s Bryan Dennison on how it detects & counters diversion tactics. 📽️ Watch what sets a purpose-built model apart: hubs.li/Q04Ctn570 #Pharma
176
Cutting list prices won’t fix US drug pricing on its own. Partha Anbil says the real differentiator is transparent channel economics, differentiated outcomes & verifiable supply, not price cuts alone. More here➡️ hubs.li/Q04DP1ky0 #PharmaExecutive #DrugPricing
1
211
What if any account team member could get answers on diversion & fraud in seconds? @Paysign’s Logan Melchione on ClaimGuardRx & what it means for program health. 📽️ Hear where it fits in strategy, forecasting & QBRs: hubs.li/Q04CsHVF0 #Pharma
220
It used to be enough for manufacturing to stay off the critical path. Not anymore. Dave Maraldo, PhD (Merck) says the real unlock is bringing manufacturing into development analytics earlier, not just at handoff. 📽 Watch it here: hubs.li/Q04DCLxr0 #PharmaManufacturing #CMC
1
240
Nearly 80% of approved pharma content sees little or no use by field teams. Nataliya Andreychuk, Co-founder & CEO of Viseven, explains why the edge is shifting from production capacity to decision quality. 🔗 See what content intelligence changes: hubs.li/Q04DqZqR0 #Pharma
183
State lawmakers are becoming the biggest force in drug pricing, moving faster than Washington. PhRMA’s Scott LaGanga joins Pharm Exec’s Mike Christel to talk PBM reform, with 7,000+ state seats on the ballot this cycle. 🎧 Listen: hubs.li/Q04DmRrw0 #PharmExec
1
193
Bolting AI onto legacy supply chain systems risks fragmented data, hallucinations & limited auditability. PAXAFE’s Mark Talens on the guardrails that build trust. 📽️ Hear what AI should act on, & what it shouldn’t: hubs.li/Q04C992k0 #Pharma #AI
1
1
230
Recruiting just 8% of all US pancreatic cancer prescribers took $2,000 an hour and equity. That’s why Hamish Brocklebank of hubs.li/Q04D2Kh80 wants to retire the term “digital twin” for “digital clones” built from real data. 📽 Watch: hubs.li/Q04D2KnF0 #PharmExec #DigitalHealth
170
Community engagement is a powerful tool, but its impact depends on how it’s done. Inside Edge Consulting Group on building trust early to widen access & drive commercial growth. 📽️ Watch what makes engagement stick: hubs.li/Q04BrtcF0 #ClinicalTrials
2
198
MFN pricing, manufacturing gaps & AI-driven trial recruitment, Michael Hollan brings in 3 experts to break down what’s shaping pharma this week. Find out more: hubs.li/Q04Cnwld0 #PharmaExecutive #PharmaIndustry
1
2
297
Cheap & valuable aren’t twins, but pharma pricing debates treat them that way. Dr. Nadine Zawadzki breaks down why ACOs reward cost-cutting over quality on The Ron Lanton Report. Listen here➡️ hubs.li/Q04Ch-d30 #PharmExec #ValueBasedCare
246
Clinical trial transparency in the EU just got more serious. The EMA and EU states are pushing sponsors harder to report results, backed by reminders and a system that flags unreported data. 🔗 Read Ed Silverman’s breakdown: hubs.li/Q04C1qBG0 #PharmExec #ClinicalTrials
2
216
Relocating a lab (or just one instrument) doesn't have to mean lost time. Agilent CrossLab shares how to move smart & stay compliant. 🔧 See how: hubs.li/Q04BWcrb0
193